Valuation as at 2026-08-14
About Pro Medicus Limited
Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform for secure email and integration products.
Source: Yahoo Finance company profile · factual description, not KashVector commentary
Pro Medicus Limited PME.AX
Healthcare · Health Information Services
What does the current price assume?
At the current price, the market appears to be pricing in about 96.0% initial revenue growth — steep enough that the model's own free cash flow would dip before recovering by year 1, even though Pro Medicus Limited's actual free cash flow is already positive.
Pro Medicus Limited's trailing free cash flow is $102.7M on 28.4% current revenue growth today. The model's reinvestment charge scales with the assumed growth rate, not the company's actual current pace — funding 96.0% growth takes substantially more reinvestment than the business is really making right now, which is what pushes the modeled figure negative before it recovers.
Pro Medicus Limited's price & financial trends
Data as at 2026-08-14
Share price · last 2 years
Revenue Per year
Free cash flow Per year
Operating margin trajectory Per year
Growth Score
Value investing scale · Buffett · Dalio · Graham
The two models, in detail
Each shown with what it says the company is worth today and what growth the current price already implies — not just a single point estimate.
Multi-Stage DCF
EV / Sales
These numbers come from running Pro Medicus Limited's revenue and margin trajectory through the Multi-Stage DCF and EV/Sales formulas above — not from any view on the news, management, or PME.AX's competitive position. What is a multi-stage DCF?
Want to test your own growth, margin, or discount-rate assumptions?Open the full interactive calculator, pre-filled with PME.AX →
More ASX stocks we've valued
Not financial advice. Multi-Stage DCF and EV/Sales valuations are highly sensitive to assumptions — small changes in growth rate, target margin, or discount rate produce large swings in output. This is a mechanical calculation, not a recommendation to buy, hold, or sell.
About this valuation
Computed on 2026-08-14 from Yahoo Finance data, using the same engine as the full Growth Stock Evaluator. Every figure above is a point-in-time snapshot of that date — change any assumption yourself in the interactive tool for a live one.
Frequently asked questions
Is Pro Medicus Limited (PME.AX) undervalued?
The Multi-Stage DCF estimates intrinsic value at $25.30 vs a price of $180.40 on 2026-08-14. This is a mechanical output from a model with genuine assumptions built in (target margin, growth fade, reinvestment) — not advice.
What does "implied growth rate" mean?
It's the reverse question: instead of assuming a growth rate and computing a value, this holds every other assumption fixed and asks what initial revenue growth rate would make the model's value equal to today's actual price. It tells you what the market is already betting on, which you can then judge for plausibility yourself.